Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft

Cancer Biology and Therapy

Volumn 7, Issue 4, 2008, Pages 596-601

  Petrangolini, Giovanna ^a   Tortoreto, Monica ^a   Perego, Paola ^a   Carenini, Nives ^a   De Cesare, Michelandrea ^a   Balsari, Andrea ^b   Zunino, Franco ^a   Pratesi, Graziella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Animal models; Camptothecin; CpG oligodeoxynucleotide; Gimatecan; Metronomic chemotherapy; Pancreatic cancer; TRAIL

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GEMCITABINE; GIMATECAN; TOPOTECAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; TUMOR XENOGRAFT;

EID: 45349090044     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.4.5548     Document Type: Article

References (41)

1. El-Rayes BF, Shields AF, Vaitkevicius V, Philip PA. Developments in the systemic therapy of pancreatic cancer. Cancer Invest 2003; 21:73-86.
2. Burris H, Moore M, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
3. Goldstein D, Carroll S, Apte M, Keogh G. Modern management of pancreatic carcinoma. Intern Med J 2004; 34:475-81.
4. Clark JW. Rubitecan. Expert Opin Investig Drugs 2006; 15:71-9.
5. De Cesare M, Pratesi G, Perego P, Carenini N, Tinelli S, Merlini L, Penco S, Pisano C, Bucci F, Vesci L, Pace S, Capocasa F, Carminati P, Zunino F. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res 2001; 61:7189-95.
6. Pratesi G, De Cesare M, Carenini N, Perego P, Righetti SC, Cucco C, Merlini L, Pisano C, Penco S, Carminati P, Vesci L, Zunino F. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin Cancer Res 2002; 8:3904-9.
7. Pratesi G, Beretta GL, Zunino F. Gimatecan, a novel camptothecin with a promising preclinical profile. Anti-Cancer Drugs 2004; 15:545-52.
8. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20:709-60.
9. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol 2005; 174:4453-60.
10. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A toll-like receptor recognizes bacterial DNA. Nature 2000; 408:659-60.
11. Pratesi G, Petrangolini G, Tortoreto M, Addis A, Belluco S, Rossini A, Selleri S, Rumio C, Menard S, Balsari A. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucletides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 2005; 65:6388-93.
12. Kemp TJ, Elzey BD, Griffith TS. Plasmacytoid dendritic cell-derived IFN-α induces TNF-related apoptosis-inducing ligand(apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol 2003; 171:212-8.
13. Kemp TJ, Moore JM, Griffith TS. Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J Immunol 2004; 173:892-9.
14. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2:420-30.
15. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-63.
16. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszweski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999; 189:1343.
17. Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 2006; 43:362-72.
18. Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, Childs R. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006; 66:7317-25.
19. Zisman A, Ng CP, Pantuck AJ, Bonavida B, Belldegrun AS. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J Immunother 2001; 24:459-71.
20. Tsai WS, Yeow W-S, Chua A, Reddy RM, Nguyen DM, Schrump DS, Nguyen DM. Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin. Mol Cancer Ther 2006; 5:2977-90.
21. Xu J, Zhou J-Y, Tainsky MA, Wu GS. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-aza-2′- deoxycytidine sensitizes human breast cancer cells to adriamycin. Cancer Res 2007; 67:1203-11.
22. Perego P, Ciusani E, Gatti L, Carenini N, Corna E, Zunino F. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells. Biochem Pharmacol 2006; 71:791-8.
23. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA 1998; 95:15553-8.
24. Grant AG, Duke D, Hermon-Taylor J. Establishment and characterization of primary human pancreatic carcinoma in continuous cell culture and in nude mice. Br J Cancer 1979; 39:143-51.
25. nd edition). Br J Cancer 1998; 77:1-10.
26. Gatti L, Supino R, Perego P, Pavesi R, Caserini C, Carenini N, Righetti SC, Zuco V, Zunino f. Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response. Cell Death Differ 2002; 9:1352-9.
27. Manzotti C, Audisio RA, Pratesi G. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis 1993; 11:5-14.
28. Gerrits CJH, de Jonge MJA, Schellens JHM, Storer G, Verweij J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 1997; 76:952-62.
29. De Cesare M, Zunino F, Pace S, Pisano C, Pratesi G. Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts. Eur J Cancer 2000; 36:1558-64.
30. Petrangolini G, Pratesi G, De Cesare M, Supino R, Pisano C, Marcellini M, Giordano V, Laccabue D, Lanzi C, Zunino F. Antiangiogenic effects of the novel camptothecin ST1481 (Gimatecan) in human tumor xenografts. Mol Cancer Res 2003; 1:863-70.
31. Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006; 24:4441-7.
32. Balsari A, Tortoreto M, Besusso D, Petrangolini G, Sfondrini L, Maggi R, Mènard S, Pratesi G. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer 2004; 40:1275-81.
33. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999; 59:5429-32.
34. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, Krug A, Rothenfusser S, Endres S, Hartmann G. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002; 169:3892-9.
35. Sfondrini L, Besusso D, Rumio C, Rodolfo M, Ménard S, Balsari A. Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. FASEB J 2002; 16:1749-54.
36. Ochi M, Ohdan H, Mitsuta H, Onoe T, Tokita D, Hara H, Ishiyama K, Zhou W, Tanaka Y, Asahara T. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology 2004; 39:1321-31.
37. Takahashi M, Ogasawara K, Takeda K, Hashimoto W, Sakihara H, Kumagai K, Anzai R, Satoh M, Seki S. LPS induces NK1.1+ ?? T cells with potent cytotoxicity in the liver of mice via production of IL-12 from Kupffer cells. J Immunol 1996; 156:2436-42.
38. Vogler M, Durr K, Jovanovic M, Debatin K-M, Fulda S. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007; 26:248-57.
39. Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res 2006; 66:4309-18.
40. Ibrahim SM, Ringel J, Schmidt C, Ringel B, Muller P, Koczan D, Thiesen HJ, Lohr M. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001; 23:72-9.
41. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas 2001; 23:251-8.